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Introduction
Drug-eluting stents (DES) were introduced into clinical practice in
2002 in order to reduce restenosis that occurred in 15–25% of
patients receiving bare-metal stents (BMS).1– 3 Subsequent trials
with different types of DES confirmed their efficacy in this
regard.4 However, late stent thrombosis was reported as early
as 2004, typically in patients discontinuing dual anti-platelet
therapy.5 At the European and World Congress of Cardiology in
Barcelona 2006, alarming data were presented on a worse long-
term prognosis following DES implantation compared with
BMS.6,7 As a result both randomized controlled trials and registry
data were scrutinized to validate these concerns, bearing in mind
the differential values of both types of studies.8,9 Furthermore,
the worldwide discussion on the long-term safety and efficacy of
DES triggered the European Society of Cardiology together with
the European Association for Percutaneous Cardiovascular Inter-
ventions to organize a forum on DES. On 27 and 28 September
2007, key opinion leaders in (interventional) cardiology and repre-
sentatives from industry and regulatory bodies gathered in the
European Heart House with the intention to review: (i) the
most recent data on the long-term efficacy (reduction of resteno-
sis, re-intervention) and safety (late stent thrombosis, myocardial
infarction, mortality) of DES and its effects on outcome (survival,
event-free survival), (ii) specific indications for DES; (iii) health
economical analyses currently performed with DES; (iv) the DES
registration process in Europe; (v) current and possible future
trial designs. The overall goal was to provide general recommen-
dations to the medical community for the use, clinical develop-
ment, and future assessment of DES.
& 2008 The European Society of Cardiology and Europa Edition. All rights reserved. For permissions please email: journals.permissions@oxfordjournals.org.
European Heart Journal (2009) 30, 152–161
doi:10.1093/eurheartj/ehn510
Safety
In several randomized controlled trials comparing sirolimus-eluting
stents (SES) or paclitaxel-eluting stents (PES) and BMS, increased
rates of death or myocardial infarction were observed at follow-up,
beyond the first year,6 –8,10 while no excess of such events
occurred in the first year.11– 14 Subsequently, several pooled ana-
lyses of individual patient-level data from these and other trials
indicated similar safety up to 4 years.15– 18
In particular, the long-term safety of DES was assessed in a
network meta-analysis, including 38 randomized controlled trials
in over 18 000 patients.18 While there was no difference in mor-
tality up to 4 years in patients initially treated with either BMS,
SES, or PES, the SES was associated with a 19% lower risk for myo-
cardial infarction (MI) as compared with BMS and 17% as com-
pared with PES.
In the latest report of the Swedish SCAAR registry (n ¼ 35 262)
presented at the ESC congress in Vienna 2007, the incidence of
death and MI were similar between DES and BMS up to 4
years.19 However, the survival curves showed a short-term survival
benefit with DES up to 1 year followed by a late catch-up.9 Thus,
the apparent early benefit is lost by an excess of subsequent
events. A pattern of lower initial and increased late mortality
rates following DES use was reported by RAVEL2,7 and the Basel
Stent Kosten Effektivita¨ts Trial (BASKET-LATE; DES: n ¼ 281)
investigators.10 While there was no significant difference in death
and MI at 3 years, this was the net result of a higher 6 month sur-
vival and a higher incidence of late (.6 months) death, or MI fol-
lowing DES. According to the authors, this latter might be the
consequence of the discontinuation of clopidogrel at 6 months.10
It is noteworthy that the impaired outcome with DES that was
reported earlier by the SCAAR investigators in patients treated
up to 2004 was no longer present in the current analysis, which
included patients treated in 2005.9,19 Additionally, the
Western-Denmark registry (n ¼ 12 395), Ontario registry data
(n ¼ 13 353), and data from the state of Massachusetts demon-
strated a trend towards a lower mortality rate following DES in
the first months, which was maintained up to 2–3 years.20– 22 Simi-
larly, in an analysis of 6129 consecutive patients from Rotterdam,
the Netherlands, the use of SES, but not PES, was associated
with a significantly higher 3 year survival as compared with
BMS.23 The survival benefit with SES became apparent as early
as 3 months. The ENDEAVOR programme, evaluating a new
zotarolimus-eluting stent, showed significantly lower cardiac
death and MI rates for the DES as compared with BMS up to 3
years.24
It should be appreciated that follow-up in different trials,
meta-analyses, and registries varies from 1 or 2 years to 5 years.
These differences should be taken into consideration when com-
paring these studies. Furthermore, it should be appreciated that
there may be important differences in both efficacy and safety
among different types of DES as well as among BMS (Figure 1).
Not all DES are equal, nor are BMS! If the trend of an early
benefit with some DES, with a later excess of death and MI as
observed in some studies, would persist, long-term outcome
beyond 5 years might gradually favour some types of BMS. This
is, of course, highly speculative! Nevertheless, it is desirable that
the investigators will continue to provide such very long-term
follow-up data.
Late stent thrombosis
Stent thrombosis has been linked to a wide variety of pathophysio-
logical mechanisms and clinical and procedural risk factors.6,25– 28 It
has been associated with mortality rates varying between 15 and
45%.29,30
Data from registries and meta-analyses6 –10,16 –24 indicated that
there is no difference in the risk of early (,30 days) and late
(.30, ,365 days) stent thrombosis between DES and BMS, but
that an excess risk emerges after more than 1 year of follow-up
(very late stent thrombosis). The incidence of angiographically
documented stent thrombosis in the combined Bern–Rotterdam
experience with PES and SES was 0.6% per year, without any
sign of reduction up to 4 years after stent implantation, and with
slightly higher rates for PES than SES.31 A comparable rate of
0.5% was observed in the SCAAR registry.9 This suggests that
endothelial healing remains impaired up to 4 years, at least in
some patients and/or with some DES. Of interest were the
recently presented 2 and 3 year follow-up of the ENDEAVOR I,
II, and III trials, which showed remarkably low rates of stent
Figure 1 Restenosis at clinically driven re-angiography (data
from the SCAAR registry presented by Dr S. James; ACC
2008). There are major differences for in-stent restenosis in
BMS ranging from 7% to 10.5% at 3 years (upper series of
curves) as well as among DES, ranging from 3.3% to 4.6% at
3 years (lower 5 curves).
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thrombosis (0.0–0.3%) and no cases of stent thrombosis after 30
days.24 Of note, these pivotal studies evaluating the relative safety
and efficacy of the zotarolimus-eluting stent were restricted to
relatively simple lesions and patients. It is possible that this
zotarolimus-eluting stent has a better safety profile than SES or
PES. However, no direct comparative data are available. The
results of the large E-Five registry and the 8800 patients random-
ized PROTECT trial are eagerly awaited.
It should be appreciated that documentation of stent thrombo-
sis by angiography underestimates the real incidence of such event,
since some of the patients with stent thrombosis develop MI, or
die without angiographic documentation of stent thrombosis. To
address this issue, new definitions were formulated by a consor-
tium of interventional cardiologists from both sides of the Atlantic,
representatives of the Food and Drug Administration (FDA), clini-
cal research organizations, and representatives from major stent
manufacturers (Figure 2).32
Efficacy
The clinical trials as well as registries consistently confirm lower
(target lesion) revascularization rates at follow-up with DES com-
pared with BMS.9,16,18,20,21,33 However, the reduction of sub-
sequent revascularization in registries was less than in clinical
trials. The absolute reduction in target vessel revascularization at
4 years in a network meta-analysis of 38 clinical trials was about
12 vs. 2–4% in the Swedish SCAAR registry at 3 years.9,18 While
the target lesion revascularization (TLR) rate in SCAAR (Swedish
Coronary and Angioplasty Registry) did not reach 6% at 3 years
in the DES arm,9 the network meta-analysis18 showed TLR rates
up to 9% at 3 years with DES, a discrepancy that was even more
apparent in patients treated with BMS and is most probably
explained by systematic angiographic follow-up in many trials,
and the lack of such angiography in the ‘real world’ registries.
Data quality in the registries may be limited by the absence of
Figure 2 ARC definitions of stent thrombosis
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event adjudication by blinded outcome assessors and lack of data
query and verification, while patient and device selections are
often operator dependent. In registries, patients treated with at
least one DES are allocated into the DES cohort regardless of
the number of simultaneously or previously implanted BMS,
although clinical events in the mixed cohort may be related to
either stent type. In many registries, the BMS group is a mixture
of many different types of bare metal devices, with different out-
comes. Similarly different DES are mixed while outcome may
vary. This was illustrated from the SCAAR registry reporting rest-
enosis rates per individual BMS types ranging from 7 to 11% at 3
years (Figure 1). For different DES 3 year restenosis rates varied
between 3.3 and 4.6%. Finally, the interpretation of long-term
follow-up data is hampered by cross-overs: patients who receive
first one type of stent and then another type of stent at a later
point of time, for example, for in-stent restenosis. Following the
‘intention to treat’ principle, all events were attributed to the
first stent that was employed, while some new events may patho-
physiologically be related to a second or third type of stent in that
patient. In the original trial protocols, secondary stent thrombosis—
stent thrombosis in a patient who had previously undergone
target-lesion revascularization—was not considered to be a stent
thrombosis. Consensus should be reached on how these events
should be classified and reported.
Drug eluting stents and bare-metal
stents in specific patient groups
In interventional cardiology as well as in other fields of medicine,
post hoc subgroup analyses should be interpreted with caution.
These may provide important directions for additional research,
but the conclusions may only be accepted if these are very
strong, consistent among all studies, and based on plausible patho-
physiology and experimental data. In general, the treatment effects
in subgroups with limited numbers of patients and events are best
estimated by the overall effects in the trials. Yet, a few subgroups
should be discussed in this report.
ST-segment elevation myocardial
infarction
Two-year follow-up of the STEMI cohort of the GRACE registry
showed a lower in-hospital mortality in the DES cohort, a similar
mortality rate from the time of discharge up to 6 months, but a
significantly higher mortality rate from 6 months to 2 years in
patients treated with DES (n ¼ 569) as compared with BMS (n ¼
1729) (HR 6.69, 95% CI 2.05–21.8).34 Survival rates following
DES or BMS were similar in both the overall population and in
the non-STEMI group. A recent meta-analysis of trials including
patients presenting with ST-segment elevation MI (eight trials—
2786 patients) showed no difference in the hard clinical endpoints
of death and MI in these high-risk patients. However, most of the
trials had a follow-up limited to 1 year.35
Multivessel coronary artery disease
The recently presented 3 year results of the Arterial Revascular-
ization Therapies Study (ARTS-II) reported the safety and
efficacy of percutaneous coronary intervention (PCI) using
SES (n ¼ 607) as compared with the randomized surgical
(n ¼ 605) and percutaneous arms (n ¼ 600) of ARTS-I for
patients with multivessel coronary artery disease.36 The
authors concluded that despite the higher clinical and angio-
graphic risk profile of the ARTS-II population, the incidence of
death/stroke/MI was significantly lower than in the ARTS-I PCI
arm and similar to the ARTS-I coronary surgery (CABG) arm.
Despite the significantly lower repeat intervention rates in
ARTS-II as compared with ARTS-I PCI, CABG remained associ-
ated with the lowest re-intervention rates compared with both
PCI groups. These findings were in line with the 3 year results
of the Argentine Randomized Study Coronary Angioplasty vs.
Coronary Bypass Surgery in Multiple Vessel Disease (ERACI-III
trial; n ¼ 675) showing similar rates of death, stroke, and MI up
to 3 years in patients treated with DES as compared with
either CABG or PCI with BMS and significantly lower repeat
revascularization in the CABG group as compared with both
PCI arms.37
Small vessels, long lesions, diabetics,
and bypass grafts
Heterogeneity of the treatment effect was suggested by an analy-
sis of the randomized BASKET-LATE trial,38 observational data
from Ontario, Canada (n ¼ 16 498),21,39 and data from a continu-
ous registry of all PCIs in Belgium (n ¼ 15 237). In these studies,
the DES benefit was apparent particularly in small vessels, long
lesions, diabetics, and bypass grafts. Among patients with dia-
betes, DES proved effective in reducing the need for revascular-
ization in almost all lesion types and regardless of recent MI
status. Among non-diabetic patients, the benefit of DES was
more limited but was apparent in long lesions, small vessels
and particularly when both adverse features co-existed. Also in
the network meta-analysis, the number needed to treat to
prevent TLR was lower in diabetic patients as compared with
non-diabetic patients.18 Of note, in a meta-analysis of pivotal ran-
domized controlled Cypher trials, significant heterogeneity in the
treatment effects was found for patients with or without dia-
betes. The 4 year cumulative survival rates among patients
without diabetes did not differ significantly between the two
groups, while the survival rate for patients with diabetes was sig-
nificantly lower in the SES group (P ¼ 0.008). Deaths from both
cardiovascular and non-cardiovascular causes in diabetics (n ¼
428) were more frequent in the SES group. In the subgroup of
patients with diabetes, stent thrombosis more than 1 year after
the procedure was adjudicated more frequently among the
patients with SES than among those with BMS. Owing to the
low number of events, these findings should be interpreted
with caution; it does not appear that they adequately explain
the observed difference in survival among patients with diabetes
in the two groups.15 Conversely, in the larger scale network
meta-analysis, no significant difference in all-cause mortality was
observed in 3679 patients with diabetes.18 Specific trials compar-
ing different stents in these high-risk patient groups are
warranted.
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Conclusions, perspectives, and
recommendations regarding efficacy and safety
of DES
† Drug eluting stents, when compared with BMS as an
initial treatment strategy, are associated with lower
subsequent revascularization rates, but an excess
risk of late stent thrombosis, which thus far, does
not seem to impact on the occurrence of hard clinical
endpoints like death and myocardial infarction up to 4
years.
† Thus far, the overall relative safety and efficacy of DES
compared with BMS appears to be consistent across
different groups of patients, albeit at various levels of
absolute benefit and risk. The long-term safety and
efficacy of DES in high-risk patient subsets such as
diabetics and patients presenting with MI remains to
be established.
† There are important differences between the various
types of stents, with dissimilar mechanical and
pharmacological properties and subsequent differ-
ences in clinical outcome: ‘Not all DES are equal,
nor are BMS’.
† Interpretation of long-term follow-up data is ham-
pered by cross-overs and mixed DES and BMS use:
patients who receive first one type of stent and
another type of stent at a later point in time, for
example, for in-stent restenosis.
† These new findings add valuable information to the
initial reports that have led to the creation of this
Task Force and call for greater attention to scientific
scrutiny and caution in the communication to the
public of sensitive scientific information. However,
the current conclusions regarding the safety and
efficacy of DES should not divert the attention from
the importance to continue development of less- or
non-thrombogenic stents.
Health economical analyses
With respect to the discussions about effectiveness and risks of
DES, and the higher costs of DES compared with BMS, health
economical analyses have been initiated in different countries.
Three analyses were presented, showing consistent results.
In Ontario, Canada, since 2003, the Ministry of Health & Long-
Term Care has allocated a funding of $12 million for DES annually
between the 12 Cardiac Care Centres in that province.39 Cost-
effectiveness was analysed using data from 16 498 patients with
at least 12 months follow-up receiving only BMS or DES from 1
December 2003–31 March 2005. Overall, the incremental cost-
effectiveness ratios (ICERs) of DES vs. BMS were ‘fairly high’
(ICER ranging from $2630—for very long and narrow lesions—
to $133 937—for short lesions in larger vessels). A significant
benefit (reduction of repeat revascularization) at acceptable
costs appeared in a limited group of patients with adverse lesion
characteristics (long lesions, small vessels) and/or diabetes.
In its first appraisal of DES reported in October 2003, the
English National Institute for Clinical Health and Excellence
(N.I.C.E.) restricted the use of DES to small vessels (,3 mm)
and long lesions (.15 mm) based on cost-effectiveness assess-
ment using a QALY-based Incremental Cost-Effectiveness method-
ology. The expected use of DES at that time was 30%, while in
practice the usage increased up to .60% of patients in the UK. In
July 2007, N.I.C.E. issued its second appraisal of DES in draft form
and concluded that DES are not cost-effective in any population
and cannot be recommended for patients with coronary artery
disease. This recommendation was driven by a lower than
expected need for repeat revascularization with BMS in unselected
patient populations, markedly lower than in the randomized con-
trolled trials, contrasting with the very high price of DES that did
not fall as expected. Furthermore, the conclusion was driven by
an increase in the cost differential between DES and BMS. This rec-
ommendation has been challenged by professional societies and
industry alike, and has been the subject of extensive debate. It
should be appreciated that the more successful the new technol-
ogy, the more rapidly and further the price of the old technology
that it is replacing is likely to fall. This may reduce the relative cost/
effectiveness of the new technology, unless its price is similarly
reduced. The appraisal committee reviewed their draft guidelines
in October 2007 and N.I.C.E. subsequently made their 3 year
review with the latest draft document issued in January 2008
(see textbox below) and did issue final guidelines in June 2008.
In the 18 month data presented from the BASKET trial,
follow-up costs were similar for both DES and BMS and relatively
low overall.38 Owing to higher stent costs, the use of DES was
associated with an ICER of E64.732. In terms of clinical endpoints,
DES proved most effective in high-risk patients and lesions, while
the study showed no improved outcome in low-risk patients and
lesions in terms of efficacy. Subgroup analyses revealed that at
18 months, the ICER for DES was favourable if the use was
limited to high-risk patients with small vessel/bypass graft stenting
(only one-third of the patients fall into these groups).
Ong et al.40 evaluated the cost-effectiveness of SES in the Rapa-
mycin Eluting Stent Evaluated at Rotterdam Cardiology Hospital
(RESEARCH) registry and concluded that the SES was not cost-
effective at 1 or 2 years follow-up when compared with BMS.
The ICER per target vessel revascularization avoided would be
E29.373 at 1 year, and E22.267 at 2 years in the total cohort.
On the basis of these results, the calculated maximum cost-
effective price after 1 year of follow-up is E1336 per SES for all-
comers, or E1023 to achieve cost-neutrality in the Netherlands.
The findings of these health-economic analyses are consistent,
indicating that DES are not cost-effective at the current price
levels for most patients undergoing PCI for stable angina, while
the use of DES can be cost-effective in a subset of patients at high
risk for restenosis. It was discussed that DES would become cost-
effective for most patients if the price-premium, relative to BMS,
would not exceed E450 (£300 Pounds Sterling). No cost-
effectiveness data on the use of DES for the life-saving indications
of PCI (unstable angina, NSTEMI, or STEMI) as compared with
either BMS use or conventional treatment are currently available.
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Conclusions, perspectives,
and recommendations
on cost-effectiveness
† Cost-effectiveness analyses are essential to fully
understand the value of BMS vs. DES and enlighten
healthcare policies. However, careful interpretation
is needed when analysing specific patient subsets
derived from clinical trials that might not reflect the
real world clinical practice.
† At the current price level, DES can be cost-effective
when applied in high-risk patients. Alternatively,
DES would be cost-effective in the majority of
patients undergoing PCI at a price premium around
E450 (£300 Pounds Sterling) above the price of com-
parable BMS, or less. It is worth noting that the incre-
mental cost-effectiveness ratio will be heavily
influenced by the costs of both the new and old tech-
nologies. The more successful the new technology,
the more rapidly and further the price of the old
technology is likely to fall. This may reduce the rela-
tive cost/effectiveness of the new technology, unless
its price is similarly reduced.
† Importantly, the available cost-effectiveness analyses
do not pertain to high-risk patients such as NSTEMI
and STEMI. Under those circumstances, PCI with
BMS was shown to portend a survival benefit over
non-interventional conventional therapy.1 It is
unknown whether this survival benefit will be ampli-
fied by the use of DES.
UPDATE: NICE appraisal July 2008
Not discussed at the meeting
† The current recommendation continues to support
the use of DES in small vessels, ,3 mm, and
lesions, .15 mm, provided that the additional costs
of the DES are £300 or less (see http://www.nice.
org.uk/Guidance/TAI52).
The DES registration process
Drug-eluting stents are combination products that consist of a
medical device with a medicinal substance as an integral part.
DES were classified as class III medical devices and require a con-
sultation with the Competent Authorities of the member states
prior to CE certification by the Notified Body. Therefore, the
Competent Authority will assess the clinical data related to
quality, safety, and usefulness of the medicinal substance. The posi-
tive assessment report of the Competent Authority is the pre-
requisite for the certification of DES by the Notified Body.
In 2007, at least 19 different DES have received Conformite´ Eur-
ope´enne (CE) mark approval, while at the time of the conference
only the first two DES (Cypher and Taxus) were approved by the
US FDA for commercial use. Of note, the US FDA has recently
given a positive review for the Endeavor and Xience-V DES. The
German Society of Cardiology reviewed the data supporting 19
DES with CE mark, as reported in 76 randomized controlled
trials. A distinction was made between studies with angiographic
or primary clinical endpoints.41 The authors used a pre-defined
decision tree to assess the level of evidence gained with the individ-
ual trials. Although the used score was not an internationally vali-
dated assessment tool for clinical studies and disregarded the fact
that several studies were also powered for secondary endpoints,
the authors concluded that only three, or at best five, out of the
19 CE-marked DES had adequate clinical documentation supporting
their use. They concluded that there is significant heterogeneity in
the requirements that are set for obtaining a CE-mark certificate.41
With the intention to harmonize the views and interests of the
notified bodies on the one hand and the medical profession on
the other hand, speakers from KEMA, BSI, TU¨V SU¨D Product
Service, CETF, EMEA, and the FDA presented their views on the
current approval process and their thoughts for modification of
the process for assessment of next generation devices. There was
agreement that novel stent technologies will be developed, and
should be made available for patient use in Europe, but also that
more extensive pre-marketing (pre-clinical and clinical) as well as
post-marketing studies might be required. A balance should be
found between pre-marketing and post-marketing evaluation with
differential follow-up timescales, also accounting for the expected
relatively short lifetime of the drug-device combination products.
Additional guidance documents are required to achieve uniformity
and consistency on the type of ‘short-term’ (pre-approval) data
needed to receive CE Mark decision and ‘long-term’ (post-approval)
data that are needed. Such documents are under development both
by the Notified Bodies and by the EMEA. It was suggested by the
clinical professionals that initial (CE mark) approval might be
obtained based on assessment of the effects of a stent (DES or
BMS) on coronary lesions (angiography, intravascular ultrasound),
stent coverage by intima (optical coherence tomography or endo-
thelial function studies), as well as 1 year clinical follow-up. In
addition, post-market clinical follow-up should be considered for
devices where identification of possible emerging risks and the
evaluation of long-term safety and performance are critical.
Careful attention should also be paid to differences in the popu-
lations enrolled in pre-market studies as compared with the actual
use after release. Finally, the interplay between a device and long-
term medical treatment, in particular, the duration, and the level
of anti-platelet therapy should also be taken into consideration.
According to the EMEA, there are at present substantial differences
in the amount and qualityof submitted data. The authority emphasized
the need for properly performed randomized controlled trials. While
there is clearly a role for both patient-based endpoints such as death,
MI, and repeat revascularizationas well as for lesion/device-based end-
points such as late lumen loss, binary restenosis, and TLR, there is no
consensus on how best to use both of these categories for trials at
different stages in the development and approval processes. Further-
more, there are many unresolved issues with regard to the selection of
comparators when evaluating new DES platforms. First, there are
studies that should use surgery or medical therapy most appropriately
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as the standard of care for the control group. Secondly, if DES are
compared with BMS, data presented from the SCAAR registry
made the point that outcomes vary greatly depending on the brand
of BMS selected (Figure 1). In future studies, it may be relevant to
compare new, investigational DES platforms to already approved
DES platforms in so-called ‘active control’ study designs. Yet, there
is no specific requirement for either BMS or DES as a control
device. When acceptable treatment alternatives exist, safety concerns
can tip the balance in the risk-benefit assessment.
A proper randomization process with adequate concealment of allo-
cation andblind adjudication of clinical endpoints is needed toavoid bias
in the interpretation of data, but this can only be achieved in larger trials
at relatively high costs. The balance between the need for robust pre-
market evaluation and the speed of innovation in cardiovascular devices
such as DES is a critical one that needs to be directly addressed to
ensure patient safety and preserve the advance of medical technology.
Representatives of the US FDA confirmed that this organization
also considers a two-staged approach: trials with a clinically relevant
composite endpoint at 1 year (cardiac death, MI, and TLR) as well as
assessment of death and MI and stent thrombosis over longer
follow-up (at yearly intervals up to 5 years). It was suggested to
use the recently established ARC-criteria for stent thrombosis
(Figure 2). Furthermore, the actual use and possible interruption of
adjunctive anti-platelet therapy should be registered. Both random-
ized clinical trials as well as properly organized registries of clinical
practice might contribute to the post-marketing assessment of
DES. In this process, it should be appreciated that new devices
often are built on already existing platforms, polymers, or drugs. A
completely new approval process may not be required for every
small modification of an existing device, although this approach
requires thorough characterization of DES through pre-clinical
evaluation. Processes can be tailored for novel devices that incor-
porate already existing and approved platforms, polymers, or drugs.
To reach a consensus on these issues, notified bodies indicated that
they will encourage and dialogue with scientific societies, in an
attempt to harmonize the relevant requirements coming from both
a device-oriented and a pharmaceutical approach. There is a need
for harmonization in interpretation and applying requirements for
quality, safety and efficacy, and guidance to applicants and/or sponsors
in planning the overall product development. Of note, the lifecycle of
medicinal products and medical devices differ considerably; while new
medicinal substances require time frames up to 15 years, the lifecycle
of medical devices is shorter, ranging between 3 to 5 years.
A glimpse into future trial design
Currently, various innovative DES types are emerging and will
become available in the coming years with the intention to avoid
the current limitations of DES. A wide variety of modifications to
the stent platform, coating, drugs, and eluting techniques are under
investigation. Abolition of neointimal hyperplasia is no longer the ulti-
mate goal, but rather the development of more biocompatible or
bioabsorbable stents facilitating adequate endothelialization.42,43 At
the same time, development of BMS continues, with new materials
and geometry. Thus, future trials should not only compare new
and established DES, but also new DES with new BMS.
Several proposals for large-scale randomized controlled trials are
under development. These trials aim at an adequate power/sample
size for hard clinical endpoints and are often conceived in a 2  2
factorial design to compare different stents and to simultaneously
assess the optimal duration of (dual) anti-platelet therapy. For
example, the PRACTICA trial might include 12 000 all-comer
patients, with a factorial design, randomizing first to treatment
with either a DES or a BMS and subsequently for receiving 12 or
36 months of dual anti-platelet therapy. FIESTA has a similar factorial
design, with a 5 year follow-up for death, MI, and repeat revascular-
ization and 10 years follow-up for all-cause mortality. Only public
funding will be sought for financing the trial. In the currently enrolling
PROTECT trial, 8800 patients will be randomized to receive
either a zotarolimus-eluting stent or an SES. Primary endpoint of
this trial will be stent thrombosis at 3 years.
On a broader scale, the Cardiac Safety Critical Path Initiative, in
which academics, industry, and regulatory authorities are joining, is
initiating a programme focused on DES thrombosis and optimal
dual anti-platelet therapy. The core of this programme is to
develop a more formalized registration approach to concomitant
evaluation of a drug and a device when there is an obligate inter-
action between the drug and the safety behaviour of the device.
Large-scale randomized trials (e.g. TRITON, OASIS 7, PLATO, and
CHAMPION) are currently evaluating the pros and cons of new anti-
platelet agents and will shed light on the balance between a possible
reduction of adverse cardiac events by more intensive long-term
anti-platelet therapy, perhaps at the costs of higher bleeding. Dual
anti-platelet therapy with the P2Y12 receptor inhibitor clopidogrel
and aspirin substantially reduces the risk of stent thrombosis.
However, low response to clopidogrel is common and increases
the risk for stent thrombosis. Clopidogrel is a pro-drug requiring
conversion to an active metabolite resulting in a slow onset of
effect. Multiple studies have demonstrated that the response to anti-
platelet therapy with either clopidogrel and aspirin is highly variable
when the responsiveness to clopidogrel is measured with
ADP-induced aggregation.44 A low level of inhibition has been
reported in 20–40% of the patients. Prasugrel-like clopidogrel is
also a pro-drug, but with substantially more rapid onset of P2Y12
inhibition and greater and more consistent platelet inhibition
without the low responders seen with clopidogrel. Recently, the
TRITON-TIMI 38 trial (n ¼ 13 608) compared prasugrel with clopi-
dogrel when given before or during PCI and continued for 15 months
in patients with acute coronary syndrome. Prasugrel reduced the risk
of MI and halved the rate of stent thrombosis both with DES and with
BMS. Prasugrel was, however, associated with an increased rate of
major bleeding and transfusion, particularly in the elderly, in patients
with a low body weight, and in those with documented cerebrovas-
cular disease.45 The net clinical benefit (death, MI, stroke, and major
bleeding) favoured Prasugrel in most patients, except in the three
subgroups mentioned above. Ongoing trials will reveal whether
the new direct P2Y12 inhibitors, e.g. cangrelor, and AZD6140, or
alternative doses of clopidogrel and prasugrel might overcome
these limitations. Subsequently several of these agents should be
tested at different treatment durations in combination with existing
or new stents. Finally, the hypothesis has been developed that
longer term dual anti-platelet therapy will not only reduce the risk
for stent thrombosis but will also slow-down disease progression.
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Conclusions, perspectives, and
recommendations for trial design,
registration processes, and
anti-platelet therapy
† The EU Commission is asked to initiate the develop-
ment of a unified guidance document for assessment
of DES. The participation of Competent Authorities
of the Member States, Notified Bodies & EMEA and
expert societies such as ESC and EAPCI is strongly
encouraged in the development of such unified
guidance for assessment. This standard should be
homogeneous in Europe and flexible in order to
allow new devices on the market. If appropriate,
the guidance document might be written in consul-
tation with the FDA.
† Randomized controlled trials pre-registration should
strive to include all-comers which should be followed
by large-scale all-comer registries to assess both the
benefits and late complications. In view of the
superior common goal of having complete unbiased
longitudinal results after current and future DES,
Industry, National Departments of Health and
Scientific Societies should co-operate to implement
prospective independent registries of all PCIs,
ideally country-wide or continent-wide, with appro-
priate quality control and follow-up connected to
official demographic registries. Attention should be
given to the choice of comparator stents, since DES
and BMS continue to develop.
† Both randomized trials and registries, reflecting the
real world clinical practice, are valuable, however,
they need to be put in their appropriate context.
Rules for reporting events, endpoint definitions, and
quality control need to be agreed upon and harmo-
nized. Re-interventions should be categorized as clini-
cally driven or non-clinically driven (e.g. angiographic
follow-up, staged procedures, and evaluation prior to
non-cardiac surgery).
† Market access should be based on efficacy as part of
‘usefulness’. Initial approval might be based on assess-
ment of restenosis (angiography, IVUS) or neointima
formation, and stent coverage (OCT, endothelial
function) including 1-year clinical follow-up. These
data should be followed by the assessment of
death, MI, and stent thrombosis over longer
follow-up (at yearly intervals up to 5 years).
† Randomized trials are required to assess the benefit,
cost-effectiveness, and ‘optimal’ dose and duration of
long-term (dual) anti-platelet therapy including the
new more potent agents. Currently, the preferred
design for prospective trials seems to be a 2  2 fac-
torial design that incorporates a double randomiz-
ation to device and anti-platelet regimen.
† Data from clinical trials and registries should be in the
public domain and academic investigators should
have access to all relevant data for independent ana-
lyses and/or pooled analyses.
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